Want to see KR:137310 full AI Analyst Report?
SD Biosensor, Inc. (137310) AI Stock Analysis
SD Biosensor, Inc.
(Korea Exchange:137310)
The score is primarily held back by weak financial performance: sustained losses, compressed margins, and weaker TTM free cash flow despite a rebound in revenue. Technicals are mixed but relatively stable, and valuation gets modest support from the ~3.15% dividend yield, though the negative P/E reflects ongoing unprofitability.
SD Biosensor, Inc. (137310) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 758.39B
- Dividend Yield
- 3.15%
- Average Volume (3M)
- 165.40K
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 0.06
- Revenue Growth
- 5.15%
- EPS Growth
- -485.12%
- Country
- KR
- Employees
- 656
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
SD Biosensor, Inc. Business Overview & Revenue Model
Company Description
SD Biosensor Inc is an in vitro diagnostic company. It is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The company researches and develops products such as...
SD Biosensor, Inc. Financial Statement Overview
Summary
Profitability has deteriorated sharply from 2021–2022 to sustained losses in 2023–TTM, with TTM losses widening and gross margin compressing further. The balance sheet is a relative strength (moderate leverage and substantial equity), and operating/free cash flow turned positive in 2024–2025, but the TTM decline in free cash flow and ongoing negative EBIT/EBITDA constrain the score.
Income Statement
26NegativeBalance Sheet
62PositiveCash Flow
44Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 738.76B | 710.58B | 694.57B | 655.68B | 2.93T | 2.93T |
| Gross Profit | 201.81B | 225.89B | 339.39B | 122.45B | 1.39T | 1.57T |
| EBITDA | -19.65B | 51.41B | -5.37B | -250.86B | 1.28T | 1.41T |
| Net Income | -729.49B | -521.41B | -98.41B | -467.71B | 911.36B | 1.09T |
Balance Sheet | ||||||
| Total Assets | 2.90T | 3.24T | 3.89T | 3.79T | 3.26T | 3.01T |
| Cash, Cash Equivalents and Short-Term Investments | 408.07B | 770.49B | 467.75B | 557.72B | 2.07T | 1.90T |
| Total Debt | 285.11B | 669.03B | 606.52B | 603.95B | 24.79B | 24.97B |
| Total Liabilities | 495.94B | 909.44B | 956.18B | 957.28B | 315.14B | 801.72B |
| Stockholders Equity | 2.40T | 2.32T | 2.92T | 2.82T | 2.94T | 2.19T |
Cash Flow | ||||||
| Free Cash Flow | 10.97B | 300.43B | 75.62B | -387.01B | 589.78B | 1.14T |
| Operating Cash Flow | 56.74B | 357.52B | 156.53B | -242.32B | 890.23B | 1.23T |
| Investing Cash Flow | 332.82B | -139.94B | -338.93B | -1.91T | 358.52B | -957.73B |
| Financing Cash Flow | -441.56B | -27.58B | -146.27B | 769.76B | -225.74B | 351.26B |
SD Biosensor, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:137310, the sentiment is Negative. The current price of 6340.00 is below the 20-day moving average (MA) of 6562.50, above the 50-day MA of 6308.20, and below the 200-day MA of 7271.52, indicating a neutral trend. The MACD of 19.59 indicates Positive momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 10.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:137310.
SD Biosensor, Inc. Peers Comparison
Overall Rating
- KR:13731049Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:137310 | 49Neutral | KRW 752.05B | -1.04 | ― | 3.15% | 5.15% | -485.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:137310 | SD Biosensor, Inc. | 6340.00 | -2828.76 | -30.85% | |
| KR:041830 | InBody Co., Ltd. | 46550.00 | 19376.13 | 71.30% | |
| KR:328130 | Lunit Inc. | 15690.00 | -4882.55 | -23.73% | |
| KR:376900 | Rokit Healthcare, Inc. | 16810.00 | -21990.00 | -56.68% | |
| KR:397030 | Aprilbio Co., Ltd. | 11810.00 | -23290.00 | -66.35% | |
| KR:445680 | Curiox Biosystems Co., Ltd. | 49400.00 | -26000.00 | -34.48% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026